Junfang Ji1,2,3, Xin Zheng2, Marshonna Forgues3, Taro Yamashita4, Eliane L Wauthier5, Lola M Reid5, Xinyu Wen6, Young Song6, Jun S Wei6, Javed Khan6, Snorri S Thorgeirsson7, Xin Wei Wang3. 1. Life Sciences Institute, Zhejiang University, Hangzhou, China. 2. University of Hawaii Cancer Center, Cancer Biology Program (Ji), Epidemiology Program (Zheng), Honolulu, HI. 3. Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD. 4. Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan. 5. Department of Cell Biology and Physiology and Program in Molecular Biology and Biotechnology, UNC School of Medicine, Chapel Hill, NC. 6. Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD. 7. Laboratory of Experimental Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Abstract
UNLABELLED: Therapies that target cancer stem cells (CSCs) hold promise in eliminating cancer burden. However, normal stem cells are likely to be targeted owing to their similarities to CSCs. It is established that epithelial cell adhesion molecule (EpCAM) is a biomarker for normal hepatic stem cells (HpSCs), and EpCAM(+) AFP(+) hepatocellular carcinoma (HCC) cells have enriched hepatic CSCs. We sought to determine whether specific microRNAs (miRNAs) exist in hepatic CSCs that are not expressed in normal HpSCs. We performed a pair-wise comparison of the miRNA transcriptome of EpCAM(+) and corresponding EpCAM(-) cells isolated from two primary HCC specimens, as well as from two fetal livers and three healthy adult liver donors by small RNA deep sequencing. We found that miR-150, miR-155, and miR-223 were preferentially highly expressed in EpCAM(+) HCC cells, which was further validated. Their gene surrogates, identified using miRNA and messenger RNA profiling in a cohort of 292 HCC patients, were associated with patient prognosis. We further demonstrated that miR-155 was highly expressed in EpCAM(+) HCC cells, compared to corresponding EpCAM(-) HCC cells, fetal livers with enriched normal hepatic progenitors, and normal adult livers with enriched mature hepatocytes. Suppressing miR-155 resulted in a decreased EpCAM(+) fraction in HCC cells and reduced HCC cell colony formation, migration, and invasion in vitro. The reduced levels of identified miR-155 targets predicted the shortened overall survival and time to recurrence of HCC patients. CONCLUSION: miR-155 is highly elevated in EpCAM(+) HCC cells and might serve as a molecular target to eradicate the EpCAM(+) CSC population in human HCCs.
UNLABELLED: Therapies that target cancer stem cells (CSCs) hold promise in eliminating cancer burden. However, normal stem cells are likely to be targeted owing to their similarities to CSCs. It is established that epithelial cell adhesion molecule (EpCAM) is a biomarker for normal hepatic stem cells (HpSCs), and EpCAM(+) AFP(+) hepatocellular carcinoma (HCC) cells have enriched hepatic CSCs. We sought to determine whether specific microRNAs (miRNAs) exist in hepatic CSCs that are not expressed in normal HpSCs. We performed a pair-wise comparison of the miRNA transcriptome of EpCAM(+) and corresponding EpCAM(-) cells isolated from two primary HCC specimens, as well as from two fetal livers and three healthy adult liver donors by small RNA deep sequencing. We found that miR-150, miR-155, and miR-223 were preferentially highly expressed in EpCAM(+) HCC cells, which was further validated. Their gene surrogates, identified using miRNA and messenger RNA profiling in a cohort of 292 HCCpatients, were associated with patient prognosis. We further demonstrated that miR-155 was highly expressed in EpCAM(+) HCC cells, compared to corresponding EpCAM(-) HCC cells, fetal livers with enriched normal hepatic progenitors, and normal adult livers with enriched mature hepatocytes. Suppressing miR-155 resulted in a decreased EpCAM(+) fraction in HCC cells and reduced HCC cell colony formation, migration, and invasion in vitro. The reduced levels of identified miR-155 targets predicted the shortened overall survival and time to recurrence of HCCpatients. CONCLUSION:miR-155 is highly elevated in EpCAM(+) HCC cells and might serve as a molecular target to eradicate the EpCAM(+) CSC population in humanHCCs.
Authors: Erno Wienholds; Wigard P Kloosterman; Eric Miska; Ezequiel Alvarez-Saavedra; Eugene Berezikov; Ewart de Bruijn; H Robert Horvitz; Sakari Kauppinen; Ronald H A Plasterk Journal: Science Date: 2005-05-26 Impact factor: 47.728
Authors: Merav Bar; Stacia K Wyman; Brian R Fritz; Junlin Qi; Kavita S Garg; Rachael K Parkin; Evan M Kroh; Ausra Bendoraite; Patrick S Mitchell; Angelique M Nelson; Walter L Ruzzo; Carol Ware; Jerald P Radich; Robert Gentleman; Hannele Ruohola-Baker; Muneesh Tewari Journal: Stem Cells Date: 2008-06-26 Impact factor: 6.277
Authors: Yi Tang; Krit Kitisin; Wilma Jogunoori; Cuiling Li; Chu-Xia Deng; Susette C Mueller; Habtom W Ressom; Asif Rashid; Aiwu Ruth He; Jonathan S Mendelson; John M Jessup; Kirti Shetty; Michael Zasloff; Bibhuti Mishra; E P Reddy; Lynt Johnson; Lopa Mishra Journal: Proc Natl Acad Sci U S A Date: 2008-02-08 Impact factor: 11.205
Authors: Jennifer Cable; Duanqing Pei; Lola M Reid; Xin Wei Wang; Sonam Bhatia; Panagiotis Karras; Jan Joseph Melenhorst; Markus Grompe; Justin D Lathia; Erwei Song; Calvin J Kuo; Ning Zhang; Richard M White; Stephanie Ky Ma; Lichun Ma; Y Rebecca Chin; Michael M Shen; Irene Oi Lin Ng; Klaus H Kaestner; Lei Zhou; Shaheen Sikandar; Clemens A Schmitt; Wei Guo; Carmen Chak-Lui Wong; Junfang Ji; Dean G Tang; Anna Dubrovska; Chunzhang Yang; Wolf R Wiedemeyer; Irving L Weissman Journal: Ann N Y Acad Sci Date: 2021-11-30 Impact factor: 6.499
Authors: Jinhua Zhang; Yuanqing Ye; David W Chang; Shu-Hong Lin; Maosheng Huang; Nizar M Tannir; Surena Matin; Jose A Karam; Christopher G Wood; Zhi-Nan Chen; Xifeng Wu Journal: Am J Pathol Date: 2018-09-08 Impact factor: 4.307
Authors: Powrnima Joshi; Mitra Kooshki; Wayne Aldrich; Daniel Varghai; Maciej Zborowski; Arun D Singh; Pierre L Triozzi Journal: Clin Exp Metastasis Date: 2016-08-26 Impact factor: 4.510